 We discuss a few companies like BioMarin BMRN, Adaptimmune ADAP, CRISPR Therapeutics CRSP, and Alnylam Pharmaceuticals ALNY with solid product portfolios, deep pipelines which make them attractive candidates for a potential takeover in 2022. 